U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION

Evaluating the feasibility and effectiveness of HIV self-testing (HIVST) among children, adolescents, and young adults in Nigeria

Brianna Lee¹, Chizoba Mbanefo², Leeleebari Sibor², Jane Nmam-Boms², Dike Kachiside², Emeka Anoje², Akudo Ikpeazu³, Deborah Carpenter¹, David Mabirizi⁴, Dan Oliver⁴, Joseph Inyang⁴, Kehinde Balogun⁶, Solomon Ejike⁶, Obinna Ogbanufe⁷, Chibozie Ornyenuobi⁷, Omodele Johnson Fagbamigbe⁷, Chidozie Meribe⁷, Dennis Onotu⁷, Jerry Gwamna⁷, David Miller², Jessica Gross³

1 Division of Global HIV and TB (DGHT), U.S. Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA; 2 Catholic Relief Services (CRS), Abuja, Nigeria; 3 Nigeria; 3 Nigeria Ministry of Health (MOH), Abuja, Federal Capital Territory, Nigeria; 4 CRS, Baltimore, MD, USA; 5 ProHealth International, Abuja, Federal Capital Territory, Nigeria; 6 APIN Public Health Initiatives, Abuja, Federal Capital Territory, Nigeria; 7 Division of Global HIV and TB (DGHT), U.S. Centers for Disease Control and Prevention (CDC), Abuja, Federal Capital Territory, Nigeria; 7 Division of Global HIV and TB (DGHT), U.S. Centers for Disease Control and Prevention (CDC), Abuja, Federal Capital Territory, Nigeria; 7 Division of Global HIV and TB (DGHT), U.S. Centers for Disease Control and Prevention (CDC), Abuja, Federal Capital Territory, Nigeria; 7 Division of Global HIV and TB (DGHT), U.S. Centers for Disease Control and Prevention (CDC), Abuja, Federal Capital Territory, Nigeria; 7 Division of Global HIV and TB (DGHT), U.S. Centers for Disease Control and Prevention (CDC), Abuja, Federal Capital Territory, Nigeria; 7 Division of Global HIV and TB (DGHT), U.S. Centers for Disease Control and Prevention (CDC), Abuja, Federal Capital Territory, Nigeria; 7 Division of Global HIV and TB (DGHT), U.S. Centers for Disease Control and Prevention (CDC), Abuja, Federal Capital Territory, Nigeria; 7 Division of Global HIV and TB (DGHT), U.S. Centers for Disease Control and Prevention (CDC), Abuja, Pederal Capital Territory, Nigeria; 7 Division of Global HIV and TB (DGHT), U.S. Centers for Disease Control and Prevention (CDC), Abuja, Pederal Capital Territory, Nigeria; 7 Division of Global HIV and TB (DGHT), U.S. Centers for Disease Control and Prevention (CDC), Abuja, Pederal Capital Territory, Nigeria; 7 Division of Global HIV and TB (DGHT), U.S. Centers for Disease Control and Prevention (CDC), Abuja, Pederal Capital Territory, Nigeria; 7 Division of Global HIV and TB (DGHT), U.S. Centers for Disease Control and Prevention (CDC), Abuja,

Oral HIVST was a highly effective strategy to identify children, adolescents, and young adults in a low prevalence country across all ages and in facility and community settings, including 1st time testers



BACKGROUND

- Estimated 171,000 children (<14 years), 72,000 adolescents (15-19 years), and 325,000 young adults (20-29 years) living with HIV in Nigeria.
- 32% of children living with HIV (CLHIV) on antiretroviral therapy vs. 95% of adults.
- High acceptance of HIVST among adolescents and youth with emerging evidence showing high acceptability, feasibility, and effectiveness of caregiverassisted HIVST in children.

METHODS

- FASTER Initiative Faith-based Action for Scaling-up Testing and Treatment for Epidemic Response
- Data Collection Oct. 2020-Sep. 2021
- Location 8 states in Nigeria: Abuja, Benue, Delta, Enugu, Imo, Lagos, Nasarawa, Rivers
- Services HIVST provided through routine program services at 280 sites
 - Settings facility and community
 - · Approaches assisted and unassisted
 - Use of OraQuick Advance© HIVST kits, which are WHO pre-qualified for individuals ≥2 years
 - Clients with a reactive HIVST result referred for confirmatory testing with a blood-based HIV test
- Population Children (2-14 years), adolescents (15-19 years), and young adults (20-29 years)
- Clients Index contacts, social network, or screened-in with risk assessment tools
- Outcome Measures
 - Feasibility: uptake by population and setting, % results returned
 - Effectiveness: Reactive HIVST positive predictive value (PPV), % linked to ART
 - Associations with confirmed HIV infections

OBJECTIVES

- Evaluate the programmatic use of HIVST among children, adolescents, and young adults in Nigeria
- Describe the feasibility and effectiveness of HIVST in these populations
- Investigate factors associated with HIVST reactivity and confirmed HIV positivity

RESULTS

- 92,489 children, adolescents, and youth received HIVST with high proportions returning results and receiving confirmatory testing (Figure 1)
- Children (2-14 years): 77% first time testers, 98% assisted, 60% in the community, 88% PPV and 1% confirmed positive
- Adolescents (15-19 years): 73% first time testers, 63% unassisted, 82% in the community, 98% PPV and 5.3% confirmed positive.
- Young Adults (20-29 years): 59% first time testers, 50% unassisted, 77% in the community, 96% PPV and 9.9% confirmed positive
- 1st Time Testers: first time testing was associated with being confirmed positive across all age groups; other associated factors varied by group (Figure 2).

CONCLUSION

- Assisted HIVST was effective in identifying CLHIV, especially in facility settings, and adolescents and young adults across community and facility settings
- · High results return and PPV across all ages
- Assisted and unassisted models can be combined and targeted by age
- Social network referral was effective among adolescents and youth
- Effective identification of adolescent boys and young men (15-24 years)

Figure 1. HIVST Use, Results Return, Positivity, Confirmatory Testing, and Linkage to ART

Children (1-14 years)











Adolescents (15-19 years)











Young Adults (20-29 years)











Figure 2. Odds of Being Confirmed HIV-Positive



Figure 3. HIV Testing in Nigeria, Oct2020-Sep2021

	Children	Adolescents	Young Adults
	(1-14 years)	(15-19 years)	(20-29 years)
Outpatient	137,154 tests	68,460 tests	303,993 tests
	1,371 positives	875 positives	8,075 positives
	(1.0% positivity)	(1.3% positivity)	(2.7% positivity)
Community	126,619 tests	218,503 tests	1,078,717 tests
	1,436 positives	5,922 positives	70,165 positives
	(1.1% positivity)	(2.7% positivity)	(6.5% positivity)
Index	29,656 tests	11,693 tests	80,952 tests
	1,457 positives	1,514 positives	18,240 positives
	(4.9% positivity)	(12.9% positivity)	(22.5% positivity)
HIVST Intervention	43,240 tests 427 positives (1.0% positivity)	34,088 tests 1,764 positives (5.3% positivity)	15,156 tests 1,475 positives (9.9% positivity)

Jessica Gross, MSN, MPH

Epidemiologist, DGHT Global Health Center LST3@cdc.gov





Previous presented: Oral Abstract FRAC2103, ICASA 2023